Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

  |  Issue: August 2018  |  

The manufacturer plans to continue discussions with the FDA to pursue approval.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Avenue Therapeutics. News release: Avenue Therapeutics announces positive topline phase 3 data for intravenous tramadol in the management of postoperative pain. 2018 May 21.
  2. Recro Pharma Inc. News release: Recro Pharma receives complete response letter from the FDA. 2018 May 24.

Related Articles

    Pain Treatments Move Closer to U.S. Market

    Two pain treatments, extended-release injectable suspension triamcinolone acetonide (Zilretta) and meloxicam, have seen movement at the U.S. Food and Drug Administration (FDA). In October, the agency approved Zilretta to treat osteoarthritis (OA) knee pain and accepted a new drug application for meloxicam to treat pain. FDA Approves Zilretta On Oct. 6, the FDA approved extended-release,…